Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have received an average rating of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $32.00.

A number of analysts have issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued an “overweight” rating on the stock. Zacks Research upgraded shares of Odyssey Therapeutics to a “hold” rating in a report on Wednesday. TD Cowen assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday. They issued a “buy” rating on the stock. Wall Street Zen upgraded shares of Odyssey Therapeutics to a “hold” rating in a report on Saturday, May 16th. Finally, Wedbush initiated coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 price objective for the company.

Insiders Place Their Bets

In other Odyssey Therapeutics news, major shareholder Tpg Gp A, Llc acquired 1,388,889 shares of the company’s stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $18.00 per share, with a total value of $25,000,002.00. Following the purchase, the insider directly owned 3,690,146 shares of the company’s stock, valued at approximately $66,422,628. This represents a 60.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Shelley Chu acquired 11,111 shares of the company’s stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $18.00 per share, with a total value of $199,998.00. Following the completion of the purchase, the director directly owned 11,111 shares in the company, valued at approximately $199,998. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 4,183,777 shares of company stock worth $75,319,986.

Odyssey Therapeutics Price Performance

Shares of NASDAQ ODTX opened at $16.43 on Tuesday. Odyssey Therapeutics has a 52-week low of $15.35 and a 52-week high of $20.30.